Pharming announces completion of enrollment in pediatric

This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency ...

Related Keywords

Netherlands ,United States ,United Kingdom ,Canada ,Japan ,London ,City Of ,Amsterdam ,Noord Holland ,Israel ,Australia ,America ,Michael Levitan ,Christina Renfroe ,Anurag Relan ,Linkedin ,Exchange Commission ,Drug Administration ,Pharming Groupnv ,Vp Investor Relations Corporate Communications ,Nasdaq ,Lifespring Life Sciences Communication ,Pharming Group ,Chief Medical Officer ,Activated Phosphoinositide ,European Economic Area ,North America ,Middle East ,Annual Report ,Allergy Clin ,Rev Allergy ,Allergy Clin Immunol ,Spring Life Sciences Communication ,Amsterdam Stock Exchange Pharm ,